Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385687170> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W4385687170 endingPage "79.13" @default.
- W4385687170 startingPage "79.13" @default.
- W4385687170 abstract "Abstract Lipid-metabolizing enzymes are important targets for small-molecule inhibitor discovery as the regulation of inflammation responses have been linked to lipid metabolism cascades controlled by these enzymes. Non-steroidal anti-inflammatory drugs inhibit enzymes in the COX pathway preventing conversion of arachidonic acid (AA) into inflammation-inducing prostaglandins. An upstream precursor to AA is the endocannabinoid 2-arachidonoyl-glycerol (2-AG), which is biosynthesized from the cleavage of arachidonate-containing diacylglycerols (DAGs) by diacylglycerol lipase beta (DAGLβ). Previous work to identify DAGLβ’s role in inflammatory function led to the creation of KT109, a DAGLβ-specific 1,2,3-triazole urea inhibitor. Primary mouse macrophages treated with KT109 showed reductions in AA and 2-AG and an increase in arachidonate-containing DAGs, demonstrating that DAGLβ is key in proinflammatory lipid regulation and signaling. These studies focused on the effects of inhibiting mouse DAGLβ, but information regarding KT109 inhibition of human DAGLβ is still lacking. Herein, we applied activity-based protein profiling (ABPP) and quantitative proteomic and lipidomic methods to determine the effectivity of KT109 inhibition in human monocytic cell line THP1. Potency (IC 50values) for DAGLβ inhibition by KT109 in human THP1 cells were comparable to the magnitude of inhibition in mouse cells. Lipidomic analysis of KT109-treated monocytic and macrophage-differentiated THP1s did not demonstrate an accumulation of arachidonate-containing DAGs. These findings show a potential difference in the expression and activity of human DAGLβ when compared to mouse DAGLβ and additional targets of KT109 in human cells. Funding and disclosures: This work was supported by the National Institute on Drug Abuse grant no. R01 DA043571." @default.
- W4385687170 created "2023-08-10" @default.
- W4385687170 creator A5000381341 @default.
- W4385687170 creator A5092793809 @default.
- W4385687170 creator A5092793810 @default.
- W4385687170 date "2023-05-01" @default.
- W4385687170 modified "2023-09-27" @default.
- W4385687170 title "Investigating DAGLβ expression and activity in human monocytes via proteomic and lipidomic profiling" @default.
- W4385687170 doi "https://doi.org/10.4049/jimmunol.210.supp.79.13" @default.
- W4385687170 hasPublicationYear "2023" @default.
- W4385687170 type Work @default.
- W4385687170 citedByCount "0" @default.
- W4385687170 crossrefType "journal-article" @default.
- W4385687170 hasAuthorship W4385687170A5000381341 @default.
- W4385687170 hasAuthorship W4385687170A5092793809 @default.
- W4385687170 hasAuthorship W4385687170A5092793810 @default.
- W4385687170 hasBestOaLocation W43856871701 @default.
- W4385687170 hasConcept C164027704 @default.
- W4385687170 hasConcept C170493617 @default.
- W4385687170 hasConcept C181199279 @default.
- W4385687170 hasConcept C185592680 @default.
- W4385687170 hasConcept C203014093 @default.
- W4385687170 hasConcept C2776914184 @default.
- W4385687170 hasConcept C46721173 @default.
- W4385687170 hasConcept C4733338 @default.
- W4385687170 hasConcept C55493867 @default.
- W4385687170 hasConcept C58017582 @default.
- W4385687170 hasConcept C8051207 @default.
- W4385687170 hasConcept C86803240 @default.
- W4385687170 hasConceptScore W4385687170C164027704 @default.
- W4385687170 hasConceptScore W4385687170C170493617 @default.
- W4385687170 hasConceptScore W4385687170C181199279 @default.
- W4385687170 hasConceptScore W4385687170C185592680 @default.
- W4385687170 hasConceptScore W4385687170C203014093 @default.
- W4385687170 hasConceptScore W4385687170C2776914184 @default.
- W4385687170 hasConceptScore W4385687170C46721173 @default.
- W4385687170 hasConceptScore W4385687170C4733338 @default.
- W4385687170 hasConceptScore W4385687170C55493867 @default.
- W4385687170 hasConceptScore W4385687170C58017582 @default.
- W4385687170 hasConceptScore W4385687170C8051207 @default.
- W4385687170 hasConceptScore W4385687170C86803240 @default.
- W4385687170 hasIssue "1_Supplement" @default.
- W4385687170 hasLocation W43856871701 @default.
- W4385687170 hasOpenAccess W4385687170 @default.
- W4385687170 hasPrimaryLocation W43856871701 @default.
- W4385687170 hasRelatedWork W1986472600 @default.
- W4385687170 hasRelatedWork W2116463461 @default.
- W4385687170 hasRelatedWork W2279911584 @default.
- W4385687170 hasRelatedWork W2599234116 @default.
- W4385687170 hasRelatedWork W2901723378 @default.
- W4385687170 hasRelatedWork W2989699927 @default.
- W4385687170 hasRelatedWork W3081705835 @default.
- W4385687170 hasRelatedWork W4296931240 @default.
- W4385687170 hasRelatedWork W4320038484 @default.
- W4385687170 hasRelatedWork W4321373565 @default.
- W4385687170 hasVolume "210" @default.
- W4385687170 isParatext "false" @default.
- W4385687170 isRetracted "false" @default.
- W4385687170 workType "article" @default.